$5.00
$26.00
bear $5.00
base $14.00
bull $26.00
margin of safety $6.00
market price* $31.32
Business condition attached to the margin of safety
Quarterly product revenue from PYRUKYND/AQVESME running well above the first-half 2026 pace (about $45 million in Q2 2026) for two or more consecutive quarters, with cash burn visibly narrowing.
Agios Pharmaceuticals is a Cambridge, Massachusetts drug developer built around one molecule, mitapivat, an oral drug that activates an enzyme in red blood cells. It is sold as PYRUKYND for pyruvate kinase (PK) deficiency, and as AQVESME for alpha- and beta-thalassemia, launched in the United States in late 2025 (also approved in Saudi Arabia; the European Commission was reviewing a positive CHMP opinion at the time of the 10-K). Sickle cell disease is still in development. Agios sold its oncology business earlier (2021 and 2024), so the large net profits in those years were one-time sale gains, not earnings from operations. What the business earns today: nothing. Cash from operations was negative every year we measured, from about -$290 million to -$410 million annually (2019-2025), and after subtracting stock compensation (about $50-60 million a year) our owner-earnings figure is roughly -$6 to -$8 per share every year. There is no positive earnings level to capitalise, so we do not credit one. Product revenue was $54 million in 2025 and $65 million in the first half of 2026 (Q2 2026: $44.7 million), a real step up after the thalassemia launch, but operating costs run several times that. Two dated facts matter: the company held about $1.2 billion in cash and securities at December 31, 2025, and it burned about $176 million in the first half of 2026, leaving roughly $1.0 billion, or about $17 per share, and there is no going-concern warning in the annual report. The filings do not show how quickly launch revenue can grow past the cost base, so growth from the thalassemia launch, a sickle cell approval, or European sales is not credited beyond what has been reported. Bear case (about $5 per share): the launch plateaus near the current pace, spending stays near $350-400 million a year, and roughly half the cash is consumed before management cuts the research budget and the remaining product revenue (Pyrukynd and Aqvesme are single-molecule, so concentration is total) covers a much smaller cost base. Shareholders keep the remaining cash and little else. Base case (about $14 per share): current revenue keeps growing modestly on the approved indications already launched, spending gradually narrows the gap, and roughly $3 per share of cash is used up before the business approaches self-funding. The value is mostly the cash pile, plus a small value for the marketed drug. Bull case (about $26 per share): the U.S. thalassemia launch, on a diagnosed population of 18,000-23,000 patients, converts at the strong pace seen in the second quarter of 2026, product revenue reaches a scale that covers most operating costs within a few years, and the drug generates positive owner earnings that are worth roughly a decade of cash flow beyond the remaining cash. What would make this wrong: a rapid, sustained launch beyond our bull case, or a clinical/regulatory setback (sickle cell) or slower prescriptions that accelerate the burn. Because the company is loss-making, the shares carry heavy risk of dilution if funding is needed after the cash is spent. We only looked at cash and filed operating results, and did not include any share-price view. Working-capital movements were not separately tagged in the filings, so they remain inside operating cash flow.